Mark Aaron Fiala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Aaron Fiala has a total of 588 co-authors. Here are the top co-authors by number of shared publications:
Ravi Vij
58 shared publications- Ravi Vij
Division of Oncology Washington University School of Medicine St Louis Missouri USA
51 shared publications - Li Ding
Washington University in St. Louis
49 shared publications - Mark Hamilton
Multiple Myeloma Research Foundation, Norwalk, Connecticut
48 shared publications - Reyka G. Jayasinghe
Washington University in St. Louis 4 Saint Louis, MO
48 shared publications - John F. DiPersio
Department of Medicine, Washington University in St. Louis, St. Louis, USA
40 shared publications
Latest Publications
- 27 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1364-1367
The association between allostatic load and monoclonal gammopathy of undetermined significance ( MGUS )
- 27 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1364-1367
The association between allostatic load and monoclonal gammopathy of undetermined significance ( MGUS )
- Open Access
- 22 June 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e86110
Impact of Financial Incentives on Electronic Health Record–Driven Recruitment of Underrepresented Communities in Research: Randomized Controlled Trial
Background: Progress in clinical trial research depends on effective recruitment to ensure adequate sample sizes and generalizability of results. Electronic health record (EHR)–based recruitment has been suggested as a potential method to address historical imbalances in trial populations, including underrepresentation of certain racial and ethnic groups. However, disparities in EHR portal uptake and use exist, particularly among these same underrepresented groups. Thus, we hypothesized that EHR-driven recruitment for research may continue to exacerbate these dynamics. Objective: In this study, we evaluated whether a financial incentive improved response rates to recruitment messages delivered through an EHR portal in an equitable fashion. Methods: A random sample of 1200 patients with diagnoses of breast, colorectal, prostate, or lung cancer and active EHR patient portal accounts received an automated recruitment message for a fictitious cross-sectional survey study, “The Social Aspects of Cancer Care,” via their EHR portal. Two strata of patients were sampled, those who identified as non-Hispanic White individuals (n=600, 50%) and those who identified as part of a historically underrepresented racial or ethnic group (n=600, 50%), and randomized to receive an offer of a US $20 monetary incentive (n=400, 33.3%) or no incentive (n=800, 66.7%). Patients were given 14 days to respond. Results: Overall, 39.3% (471/1200) of participants viewed the recruitment message, and 13.3% (159/1200) responded that they were interested. Response rates were higher ( P <.001) among non-Hispanic White patients (108/600, 18%) than among African American or Black patients (32/456, 7%) and members of other racial or ethnic groups (18/144, 12.5%). Older patients (≥65 years) were less likely to view the recruitment message (244/720, 33.9% vs 230/480, 47.9%; P =.001) and respond (72/720, 10% vs 82/480, 17.1%; P =.002). Sex was not significantly associated with viewing the message or response outcomes ( P =.45 and P =.19, respectively). No differences were observed in response rate for the incentive cohort compared to the cohort with no incentive (60/400, 15% vs 96/800, 12%; P =.21). Conclusions: Patients with cancer who identify as part of a historically underrepresented group were less likely to view and respond to recruitment messages for research studies through their EHR patient portal. Age was also found to significantly impact engagement, with older patients less likely to view and respond. Finally, a modest US $20 financial incentive was not found to significantly impact patient engagement.
- 22 June 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e86110
Open AccessImpact of Financial Incentives on Electronic Health Record–Driven Recruitment of Underrepresented Communities in Research: Randomized Controlled Trial
Background: Progress in clinical trial research depends on effective recruitment to ensure adequate sample sizes and generalizability of results. Electronic health record (EHR)–based recruitment has been suggested as a potential method to address historical imbalances in trial populations, including underrepresentation of certain racial and ethnic groups. However, disparities in EHR portal uptake and use exist, particularly among these same underrepresented groups. Thus, we hypothesized that EHR-driven recruitment for research may continue to exacerbate these dynamics. Objective: In this study, we evaluated whether a financial incentive improved response rates to recruitment messages delivered through an EHR portal in an equitable fashion. Methods: A random sample of 1200 patients with diagnoses of breast, colorectal, prostate, or lung cancer and active EHR patient portal accounts received an automated recruitment message for a fictitious cross-sectional survey study, “The Social Aspects of Cancer Care,” via their EHR portal. Two strata of patients were sampled, those who identified as non-Hispanic White individuals (n=600, 50%) and those who identified as part of a historically underrepresented racial or ethnic group (n=600, 50%), and randomized to receive an offer of a US $20 monetary incentive (n=400, 33.3%) or no incentive (n=800, 66.7%). Patients were given 14 days to respond. Results: Overall, 39.3% (471/1200) of participants viewed the recruitment message, and 13.3% (159/1200) responded that they were interested. Response rates were higher ( P <.001) among non-Hispanic White patients (108/600, 18%) than among African American or Black patients (32/456, 7%) and members of other racial or ethnic groups (18/144, 12.5%). Older patients (≥65 years) were less likely to view the recruitment message (244/720, 33.9% vs 230/480, 47.9%; P =.001) and respond (72/720, 10% vs 82/480, 17.1%; P =.002). Sex was not significantly associated with viewing the message or response outcomes ( P =.45 and P =.19, respectively). No differences were observed in response rate for the incentive cohort compared to the cohort with no incentive (60/400, 15% vs 96/800, 12%; P =.21). Conclusions: Patients with cancer who identify as part of a historically underrepresented group were less likely to view and respond to recruitment messages for research studies through their EHR patient portal. Age was also found to significantly impact engagement, with older patients less likely to view and respond. Finally, a modest US $20 financial incentive was not found to significantly impact patient engagement.
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214703
Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy
A monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression. We performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression. Twenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83, p = 0.029) and change in WM microstructure (β = 0.175, 95% CI 0.029-0.32, p = 0.029). Neither OEF nor CBF was independently associated with cognitive decline. Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214703
Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy
A monogenic, age-related cerebral small vessel disease (cSVD), retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), causes accelerated vascular dementia, vision loss, and premature death. Given knowledge is limited regarding its pathophysiology, we examined the natural history of progression in imaging and cognitive endpoints to define the rate and variability of progression in a prospective RVCL-S cohort. We hypothesized that cerebral blood flow (CBF) and oxygen extraction fraction (OEF), as metrics of cerebral hypoxia-ischemia, would be associated with neurologic disease progression. We performed sequential brain MRI and a cognitive battery in a prospective RVCL-S cohort. Arterial spin labeling and asymmetric spin echo quantified CBF and OEF in normal-appearing white matter (WM), respectively. Three neuroimaging endpoints of cSVD included the following: log-transformed, normalized fluid-attenuated inversion recovery WM hyperintensity (WMH) volume; WM microstructure using mean diffusivity; and normalized WM volume. Five cognitive and motor endpoints included Digit Symbol Substitution Test (DSST), category fluency, free recall, Montreal Cognitive Assessment (MoCA), and gait speed. Linear mixed-effects models examined age, CBF, and OEF in association with neuroimaging and cognitive progression. Twenty-five participants, aged 23-68 years (median 47 years, 56% female), underwent 151 scans over a median (25th, 75th) of 2.2 (1.8, 4.4) years. All neuroimaging and cognitive endpoints progressed over time, except for MoCA. Of neuroimaging endpoints, WMH volume demonstrated the largest rate of change (+31.3%/year, 95% CI 20.8%-42.3%). Of cognitive endpoints, DSST, a metric of processing speed, showed the steepest decline (-13.1 T-score points/decade, 95% CI -21.2 to -5.32), followed by free recall and category fluency (-5 [-7.9 to -2.4] and -4.1 [-7.2 to -1.2] T-score points per decade, respectively). The age at first brain lesion was estimated to be 30.6 (23.8, 35.8) years, modeled from individual WMH volume trajectories. In multivariable analysis, OEF, but not CBF, was independently associated with WMH growth (β = 3.73, 95% CI 0.63-6.83, p = 0.029) and change in WM microstructure (β = 0.175, 95% CI 0.029-0.32, p = 0.029). Neither OEF nor CBF was independently associated with cognitive decline. Elevated OEF in at-risk WM was associated with progression in WMH and impairment in WM microstructure, suggesting a role for tissue hypoxia-ischemia in underlying RVCL-S pathophysiology. Cerebral OEF holds promise as a predictive biomarker to risk-stratify patients with RVCL-S and other forms of cSVD.
- 17 January 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e591-e595
A Call for Compassion: How You Can Help Get Multiple Myeloma Added to the Social Security Administration’s Compassionate Allowances List
- 17 January 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e591-e595
A Call for Compassion: How You Can Help Get Multiple Myeloma Added to the Social Security Administration’s Compassionate Allowances List
- Open Access
- 15 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 723-734
Disparities in Allogeneic Hematopoietic Stem Cell Transplantation Among Acute Myeloid Leukemia Patients
- 15 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 723-734
Open AccessDisparities in Allogeneic Hematopoietic Stem Cell Transplantation Among Acute Myeloid Leukemia Patients
- Top Cited PapersOpen Access
- 9 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 224-246
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.
- 9 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 224-246
Top Cited PapersOpen AccessA single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 151-158
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma
PURPOSE: This study aimed to determine if high-deductible health plan (HDHP) enrollment contributes to financial burden and hinders access to care for patients with multiple myeloma (MM). MATERIALS AND METHODS: Patients diagnosed with MM from 2010 to 2020 were identified in Merative MarketScan, an employer-based health insurance database. Primary outcomes were total health care and out-of-pocket (OOP) costs in the year after diagnosis. Secondary outcomes included time to treatment initiation and stem-cell transplant receipt. Multivariable analyses using linear, logistic, and Cox regression were performed, as appropriate. Covariates included age, sex, year diagnosed, comorbidities, data provider, and stem-cell transplant receipt. RESULTS: The cohort included 4,029 patients; 17.6% were enrolled on HDHPs. HDHP enrollees were younger (mean age, 54.9 v 55.5 years; P = .036). Over the first year, mean total and OOP costs were $406,401 in US dollars (USD) and $9,220 USD for HDHP enrollees, respectively, versus $386,802 USD ( P = .027) and $7,021 USD ( P < .001) for the standard plan enrollees. There was no statistically significant difference in total cost (β = 11; P = .999) but mean OOP costs were $2,544 USD (β = 2,544; P < .001) higher for HDHP enrollees after adjusting for covariates. The additional OOP costs incurred in the first 2 months, presumably because of deductibles, and after the deductible reset. Contrary to our hypothesis, HDHPs enrollees had shorter time to treatment initiation (median, 20 v 22 days; hazard ratio, 1.18; P < .001) and were more likely to receive a stem-cell transplant (55.1% v 47.6%; odds ratio, 1.25; P = .010), after adjusting for covariates. CONCLUSION: Compared with standard plan enrollees, OOP costs were higher for HDHP enrollees in the year after diagnosis, but HDHP enrollment was not associated with delays in treatment initiation or reduced access to stem-cell transplant.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (1) , 151-158
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma
PURPOSE: This study aimed to determine if high-deductible health plan (HDHP) enrollment contributes to financial burden and hinders access to care for patients with multiple myeloma (MM). MATERIALS AND METHODS: Patients diagnosed with MM from 2010 to 2020 were identified in Merative MarketScan, an employer-based health insurance database. Primary outcomes were total health care and out-of-pocket (OOP) costs in the year after diagnosis. Secondary outcomes included time to treatment initiation and stem-cell transplant receipt. Multivariable analyses using linear, logistic, and Cox regression were performed, as appropriate. Covariates included age, sex, year diagnosed, comorbidities, data provider, and stem-cell transplant receipt. RESULTS: The cohort included 4,029 patients; 17.6% were enrolled on HDHPs. HDHP enrollees were younger (mean age, 54.9 v 55.5 years; P = .036). Over the first year, mean total and OOP costs were $406,401 in US dollars (USD) and $9,220 USD for HDHP enrollees, respectively, versus $386,802 USD ( P = .027) and $7,021 USD ( P < .001) for the standard plan enrollees. There was no statistically significant difference in total cost (β = 11; P = .999) but mean OOP costs were $2,544 USD (β = 2,544; P < .001) higher for HDHP enrollees after adjusting for covariates. The additional OOP costs incurred in the first 2 months, presumably because of deductibles, and after the deductible reset. Contrary to our hypothesis, HDHPs enrollees had shorter time to treatment initiation (median, 20 v 22 days; hazard ratio, 1.18; P < .001) and were more likely to receive a stem-cell transplant (55.1% v 47.6%; odds ratio, 1.25; P = .010), after adjusting for covariates. CONCLUSION: Compared with standard plan enrollees, OOP costs were higher for HDHP enrollees in the year after diagnosis, but HDHP enrollment was not associated with delays in treatment initiation or reduced access to stem-cell transplant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
Pearson R correlation values between bulk RNA expression and scRNA expression in PCs for target genes.